| Primary reference | Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORgammat Inverse Agonist., Cherney RJ, Cornelius LAM, Srivastava A, Weigelt CA, Marcoux D, Duan JJ, Shi Q, Batt DG, Liu Q, Yip S, Wu DR, Ruzanov M, Sack J, Khan J, Wang J, Yarde M, Cvijic ME, Mathur A, Li S, Shuster D, Khandelwal P, Borowski V, Xie J, Obermeier M, Fura A, Stefanski K, Cornelius G, Tino JA, Macor JE, Salter-Cid L, Denton R, Zhao Q, Carter PH, Dhar TGM, ACS Med Chem Lett. 2020 Mar 31;11(6):1221-1227. doi:, 10.1021/acsmedchemlett.0c00063. eCollection 2020 Jun 11. PMID:32551004 |